Everything tagged "growth" across the TickerSpark archives.
Macy's is showing real operational progress, with Q1 comparable sales up 3.0% and stronger performance at Bloomingdale's and Bluemercury. The stock remains a Buy as the Bold New Chapter strategy gains traction, though debt and uneven category trends still matter.
PVH is a Buy as direct-to-consumer growth, e-commerce strength, and brand-level product momentum support a recovery story. Tariffs, leverage, and weak EMEA trends remain the main offsets.
Argan is benefiting from a $2.8 billion backlog, strong execution, and exposure to gas-fired power projects tied to data centers and electrification. The stock screens as a Buy, but concentration and fixed-price project risk keep the profile cyclical.
REX American Resources combines strong liquidity, improving earnings, and a major One Earth expansion with carbon-capture upside. The stock looks attractive for investors who can tolerate commodity-cycle volatility and policy dependence.
MongoDB has reaccelerated on Atlas strength, AI search adoption, and improving cash generation, but the stock still trades at a premium that leaves little room for execution missteps.
IES Holdings posted explosive Q3 growth across its data-center-linked segments, but the stock already prices in much of the upside. Our Hold view reflects strong execution, a clean balance sheet, and a fair value estimate of $320.
Medtronic is shifting from a slow-growth story to an execution-led reacceleration, with broad-based Q1 strength across cardiovascular, neuroscience, and medical surgical. The stock earns a Buy as growth platforms like Affera, Hugo, and Micra support a fair value of $99.
Sprinklr combines modest revenue growth, improving AI-driven product traction, and a discounted valuation with still-weak earnings momentum. The stock looks more like an execution-sensitive Hold than a clean growth story.
Abivax is a catalyst-driven biotech centered on obefazimod, with long-term ulcerative colitis durability data and a cash runway into Q4 2027. The stock offers meaningful upside if Phase 3 execution holds, but the valuation already prices in a lot of success.
GitLab combines strong revenue growth, expanding AI product traction, and solid cash generation, but the stock already prices in much of the upside. The report lands on a Hold with a fair value near the current trading range.
Novartis is navigating Entresto generic pressure with strong growth from Kisqali, Pluvicto, Leqvio, and Kesimpta. The stock looks durable, but valuation and near-term earnings pressure keep the stance at Hold.
STMicroelectronics is rebounding across automotive, industrial, and communications, with a growing AI data-center opportunity. The stock looks more like a Hold than a Buy until margins and execution improve.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime